SCHEMBL10140760

SCHEMBL10140760

COc1c(-c2ccc(Cl)nc2)nn(C)c1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 3/20 0.41
NAPRT Q6XQN6 1/20 0.39
PDE10A Q9Y233 1/20 0.38
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 1/20 0.35
ADCY10 Q96PN6 2/20 0.35
HSD17B10 Q99714 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
CHEK1 O14757 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PPARD Q03181 1/20 0.33
GAA P10253 1/20 0.33
GFER P55789 1/20 0.33
NEK2 P51955 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
KCNQ3 O43525 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140757 0.90 PDE10A (0.41) KMONAPRTPDE10AKDM4EALDH1A1
SCHEMBL10173134 0.84 JMJD6 (0.44) KDM4EALDH1A1HPGDHTT
SCHEMBL10140710 0.80 TP53 (0.46) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL10140871 0.80 MAPT (0.39) KMOKDM4EALDH1A1HPGDMEN1
SCHEMBL10140393 0.79 TP53 (0.48) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL10140698 0.79 PTGDR2 (0.39) KMOALDH1A1HPGDHSD17B10MEN1
SCHEMBL10140727 0.75 MKNK1 (0.49) KMOALDH1A1MEN1KMT2A
SCHEMBL28906165 0.70 PDE10A (0.39) PDE10AKDM4EALDH1A1HPGDHTT
SCHEMBL30111779 0.70 PDE10A (0.39) PDE10AKDM4EALDH1A1HPGDHTT
SCHEMBL16258975 0.70 KDM4E (0.46) KDM4EALDH1A1HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805939-B1 Heterocyclic compounds as factor IXA inhibitors. MERCK SHARP & DOHME (US) 2018-06-27 EP disclosed
EP-2805939-A1 Heterocyclic compounds as factor IXA inhibitors. Merck Sharp & Dohme Corp. (US) 2014-11-26 EP disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 KMO 3060/4885NAPRT 529/4885PDE10A 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.